| Original language | English (US) |
|---|---|
| Pages (from-to) | 5398-5401 |
| Number of pages | 4 |
| Journal | Vaccine |
| Volume | 38 |
| Issue number | 34 |
| DOIs |
|
| State | Published - Jul 22 2020 |
Keywords
- COVID-19
- Influenza vaccines
- PPV23 vaccine
- Transmission
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology(all)
- veterinary(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Vaccine, Vol. 38, No. 34, 22.07.2020, p. 5398-5401.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality
AU - Thindwa, Deus
AU - Garcia Quesada, Maria
AU - Liu, Yang
AU - Bennett, Julia
AU - Cohen, Cheryl
AU - Knoll, Maria Deloria
AU - von Gottberg, Anne
AU - Hayford, Kyla
AU - Flasche, Stefan
N1 - Funding Information: DT is funded by the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal Pathogens (MPRU) from the UK Government. MGQ, MDK, KH, and JB, were supported by the World Health Organisation (WHO), as a subaward from a Bill and Melinda Gates Foundation (BMGF) grant [OPP1189065/INV-010429]. YL is funded by the National Institute for Health Research (NIHR; 16/137/109) and the BMGF (INV-003174). CC and AvG receive grant support through their institution from Sanofi Pasteur. SF is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z). The funders had no involvement in the study design; collection, analysis and interpretation of data; writing of the report; or decision to submit the article for publication. However, Adam L. Cohen, Shalini Desai, Raymond Hutubessy and Ann Lindstrand who are employed by WHO provided helpful comments on the design of the study, the interpretation of the data and the writing of the manuscript. Funding Information: DT is funded by the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal Pathogens (MPRU) from the UK Government. MGQ, MDK, KH, and JB, were supported by the World Health Organisation (WHO), as a subaward from a Bill and Melinda Gates Foundation (BMGF) grant [ OPP1189065/INV-010429 ]. YL is funded by the National Institute for Health Research (NIHR; 16/137/109 ) and the BMGF ( INV-003174 ). CC and AvG receive grant support through their institution from Sanofi Pasteur. SF is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z ). The funders had no involvement in the study design; collection, analysis and interpretation of data; writing of the report; or decision to submit the article for publication. However, Adam L. Cohen, Shalini Desai, Raymond Hutubessy and Ann Lindstrand who are employed by WHO provided helpful comments on the design of the study, the interpretation of the data and the writing of the manuscript. Funding Information: We would like to thank Adam L. Cohen, Shalini Desai, Raymond Hutubessy and Ann Lindstrand of the World Health Organization, Geneva, Switzerland, for insightful discussions at all stages of this work. We would like to thank all of the PSERENADE Team site investigators who contributed IPD surveillance data to the global serotype distribution analysis. The PSERENADE project is funded by the Bill & Melinda Gates Foundation and the World Health Organization.
PY - 2020/7/22
Y1 - 2020/7/22
KW - COVID-19
KW - Influenza vaccines
KW - PPV23 vaccine
KW - Transmission
UR - http://www.scopus.com/inward/record.url?scp=85087021304&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087021304&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2020.06.047
DO - 10.1016/j.vaccine.2020.06.047
M3 - Comment/debate
C2 - 32600911
AN - SCOPUS:85087021304
SN - 0264-410X
VL - 38
SP - 5398
EP - 5401
JO - Vaccine
JF - Vaccine
IS - 34
ER -